HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
Our centers are performing as expected or even better
Our centers are performing as expected or even better
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Revolutionary technology will further boost OneSource’s scientific services offerings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Subscribe To Our Newsletter & Stay Updated